Document:

Second Amendment to the Amended and Restated Employee Stock Purchase Plan

 Exhibit 10. 9 
 SECOND AMENDMENT TO THE 
 AMGEN INC. AMENDED AND RESTATED 
 EMPLOYEE STOCK PURCHASE PLAN 
 Effective
January 1, 2008, the Amgen Inc. Amended and Restated Employee Stock Purchase Plan (the “Plan”) is hereby amended as follows (such amended language is indicated in italics): 
  

	 	1.	Section 4 of the Plan is hereby amended in its entirety as follows: 

 “4. GRANT OF RIGHTS; OFFERING 
 The Board or the Committee may from time to time
grant or provide for the grant of rights to purchase Common Stock of the Company under the Plan to eligible employees (an “Offering”) on a date or dates (the “Offering Date(s)”) selected by the Board or the Committee; provided
that no Offering shall occur in 2008 before March 1, 2008. Each Offering shall be in such form and shall contain such terms and conditions as the Board or the Committee shall deem appropriate. If an employee has more than one right
outstanding under the Plan, unless he or she otherwise indicates in agreements or notices delivered hereunder: (1) each agreement or notice delivered by that employee will be deemed to apply to all of his or her rights under the Plan, and
(2) a right with a lower exercise price (or an earlier-granted rights, if two rights have identical exercise prices), will be exercised to the fullest possible extent before a right with a higher exercise price (or a later-granted rights, if
two rights have identical exercise prices) will be exercised. The provisions of separate Offerings need not be identical but each Offering shall include (through incorporation of the provisions of this Plan by reference in the Offering or otherwise)
the substance of the provisions contained in paragraphs 5 through 8, inclusive.” 
  

	 	2.	Section 5(b)(i) is hereby amended in its entirety as follows: 

 “(i) the date on which such right is granted shall be the “Offering Date” of such right for all purposes, including (if applicable to an Offering) determination of the exercise price of such
right, provided, however, that if the fair market value of the Common Stock on the date on which such right is granted is less than the fair market value of the Common Stock on the first day of the Offering, then, solely for the purposes of
determining the exercise price of such right, the first day of the Offering shall be the “Offering Date” for such right;” 
  

	 	3.	Section 5(b)(ii) is hereby amended in its entirety as follows: 

 “(ii) the Purchase Period (as defined in subparagraph 6(a)) for such right shall begin on its Offering Date and end coincident with the end of such Offering; and” 
  

	 	4.	Section 6(a) is hereby amended in its entirety as follows: 

 “(a) On each Offering Date, each eligible employee, pursuant to an Offering made under the Plan,
shall be granted the right to purchase up to the number of shares of Common Stock of the Company purchasable with a percentage designated by the Board or the Committee not exceeding fifteen percent (15%) of such employee’s Earnings (as
defined in subparagraph 7(a)) during the period which begins on the Offering Date (or such later date as the Board or the Committee determines for a particular Offering) and ends on the date stated in the Offering, which date shall be no more
than twenty-seven (27) months after the Offering Date (the “Purchase Period”). Notwithstanding the foregoing, the fifteen percent (15%) limit set forth in the prior sentence shall be increased to thirty percent (30%) for
determining the number of shares of Common Stock purchasable during the Offering that begins on March 1, 2008. In connection with each Offering made under this Plan, the Board or the Committee shall specify a maximum number of shares which
may be purchased by any employee as well as a maximum aggregate number of shares which may be purchased by all eligible employees pursuant to such Offering. In addition, in connection with each Offering which contains more than one Exercise Date (as
defined in the Offering), the Board or the Committee may specify a maximum aggregate number of shares which may be purchased by all eligible employees on any given Exercise Date under the Offering. If the aggregate purchase of shares upon exercise
of rights granted under the Offering would exceed any such maximum aggregate number, the number of shares purchased for each participant shall be adjusted pro rata in accordance with the method set forth in the Offering. The amount of any
accumulated payroll deductions remaining in each participant’s account will be distributed in cash to the participant, without interest, as soon as administratively practicable following the applicable Exercise Date.  
 To record this Second Amendment to the Plan as set forth herein, the Company has caused its authorized officer to execute this document this 14th day of December 2007.

  

			
	AMGEN INC.
		
	By:	 	/s/    BRIAN MCNAMEE
	Title:	 	Senior Vice President, Human ResourcesFifth Amendment to the Amgen Nonqualified Deferred Compensation Plan

 Exhibit 10.33 
 FIFTH AMENDMENT TO THE 
 AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN 
 AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2005 
 Article I (Definitions) of the Amgen Nonqualified Deferred Compensation Plan as Amended and Restated Effective January 1, 2005 (the “Plan”) is hereby amended effective January 1, 2008, accordingly: 
  

	1.	The definition of “Annual Base Salary” shall be amended in its entirety to read as follows: 

 “Annual Base Salary” shall mean a Participant’s compensation consisting only of regular salary paid by any Employer for services rendered
during the Plan Year and excluding any other compensation. With respect to any member of the Board, Annual Base Salary shall mean the member’s annual retainer, chair fees, Board meeting fees, and Committee meeting fees. 
  

	2.	The definition of “Annual Bonus” shall be amended in its entirety to read as follows: 

 “Annual Bonus” shall mean any compensation earned by a Participant during a Plan Year that constitutes a commission paid to a salesperson or
that is paid pursuant to the Amgen Global Management Incentive Plan (GMIP), the Amgen Inc. Executive Incentive Plan (EIP), or an equivalent bonus program. All other compensation is excluded. 
 To record this Fifth Amendment to the Plan as set forth herein, the Company has caused its authorized officer to execute this document this 14th day of December 2007.

  

			
	AMGEN INC.
		
	By:	 	/s/    BRIAN MCNAMEE
	Title:	 	Senior Vice President, Human ResourcesAmendment No. 6 to the Enbrel Supply Agreement

 Exhibit 10.63 
 AMENDMENT NO. 6 
 TO THE 
 ENBREL® SUPPLY
AGREEMENT 
 This Amendment No. 6 (“Amendment No. 6”) is made this 27th day of November, 2007 (the “Amendment
No. 6 Effective Date”) by and among IMMUNEX CORPORATION, a corporation of the State of Washington, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, U.S.A., together with its
Affiliates (“Immunex”), WYETH (formerly known as American Home Products Corporation), a corporation of the State of Delaware having its corporate headquarters at Five Giralda Farms, Madison, New Jersey 07940, U.S.A. and acting
through its Wyeth Pharmaceuticals Division (“Wyeth”), and BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, (formerly doing business as “Boehringer Ingelheim Pharma KG”) a German corporation having a place of business at
Birkendorfer Straße 65, 88397 Biberach an der Riss, Federal Republic of Germany (“BIP”), and amends the Enbrel Supply Agreement effective as of November 5, 1998, by and among Immunex, Wyeth, and BIP, and as amended (the
“Agreement”). 
 WHEREAS, Immunex, Wyeth and BIP have entered into a certain
Agreement for BIP’s supply of Enbrel® (etanercept) to Immunex and Wyeth; 
 WHEREAS, the Parties originally intended to transfer the manufacturing process to a Second Generation Process, called the “T2 Process”; 
 WHEREAS, the Parties have agreed that an alternative Second Generation Process, herein referred to as “SFP”, shall be used instead of the T2 Process to manufacture Enbrel. 
 WHEREAS, pursuant to Section 23.9 of the Agreement, the Agreement may only be amended and supplemented by a written instrument signed by the
Parties. 
 NOW THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties hereto, each intending to be legally bound, hereby agree as follows: 
 1. Capitalized Terms. All initially capitalized terms used herein and not defined shall have the meanings set forth in the Agreement as amended. 
 2. Amended Definitions. Sections 1.55, 1.56 and 1.64 of the Agreement shall be amended and restated as follows: 
  

	 	1.55	 “Second Generation Process” shall refer to the manufacturing process codenamed “SFP” (hereinafter the term SFP shall refer to the Second
Generation Process) for using the Cell Line, including defined procedures, equipment and analytical methodologies for in-process control, release testing and Product characterization, that is used to produce the Second Generation Product. The
process will be subject to (a) pre-FDA Product 

  

 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential
treatment that has been filed with the Securities and Exchange Commission. 
 1 

 
Exhibit 10.63 
 approval changes and
(b) post-FDA Product approval changes, in each case as may be agreed upon in writing from time to time by the Parties. BIP shall not unreasonably withhold its agreement to such changes after agreement of the Parties on the commercial impact of
any such changes. 
  

	 	1.56	“Second Generation Product” shall mean Product manufactured using the Second Generation Process. 

  

	 	1.64	“Working Cell Bank” shall mean a vialed collection of serially subcultivated cells generated by Immunex and/or Wyeth that is derived from the Master Cell Bank. The
Working Cell bank is used to establish seed cultures of the Cell Line to initiate the Process. 

 3. New Definitions.
Section 1.66 of the Agreement shall be amended to add the following new definitions: 
  

			
	 	  	 Section

	 “Baseline Accepted Unused Capacity”
	  	5.10(a)(4)(i)
	 “Baseline Production Assumptions”
	  	5.3(c)(1)
	 “Commercial Bulk Drug Substance”
	  	5.3(c)(1)(C)
	 “Initial Price Adjustment”
	  	5.3(c)(1)(A)
	 “Multiple Product Complexity Premium”
	  	5.3(c)(3)
	 “Original Biberach Facility”
	  	5.10(a)(4)(i)
	 “Scope of Work”
	  	3.5(b)(1)
	 “Statement of Cost”
	  	3.5(b)(1)
	 “Subsequent Price Adjustments”
	  	5.3(c)(2)
	 “Transition Year”
	  	5.3(c)(3)(A)(iv)
	 “Working Cell Bank Safety Stock”
	  	12.1(a)

 4. Implementation of Second Generation Process. Section 3.5(b) of the Agreement shall
be amended and restated as follows: 
  

	 	3.5	Relocation of Manufacturing and Conversion to Second Generation Process. 

  

	 	(b)	Conversion to Second Generation Process. 

  

	 	(1)	At the request of Immunex and Wyeth, BIP shall undertake to convert from manufacturing the Product using the First Generation Process to using the Second Generation Process in
accordance with manufacturing procedures and protocols set forth in Amendment No. 6, Exhibit A (the “Scope of Work” or “SOW”). The costs to be paid by Immunex and Wyeth for such conversion are set forth in Amendment
No. 6, Exhibit A, Appendix II (the “Statement of Costs”). 

  

 2 

 Exhibit 10.63 
 5. Control of Master Cell Bank and Working Cell Bank. Section 12.1 of the Agreement shall be amended and restated as follows: 
  

	 	12.1	Control of Master Cell Bank and Working Cell Bank. Immunex and Wyeth shall retain control of all Master Cell Bank(s). [*] 

  

	 	(a)	Supply of the Working Cell Bank and Certificates of Analysis. [*]. 

  

	 	(b)	Working Cell Bank. [*]. 

  

	 	(c)	Other information relating to the Working Cell Bank. [*]. 

  

	 	(d)	BIP Biosafety Concerns. [*]. 

  

	 	(e)	Immunex’s and Wyeth’s Representations and Warranties. [*]. 

 6. Pricing of Second Generation Product. Sections 5.3(c) and 5.3(d) of the Agreement shall be amended and restated as follows: 
  

	 	5.3	Adjustment of Bulk Drug Substance Pricing Based on Product Assumptions. 

  

	 	(c)	Second Generation Product. Pricing of Second Generation Product Bulk 

 Drug Substance shall be calculated as set forth below. 
  

	 	(1)	Initial Price Adjustment. [*]. 

  

	 	(d)	First Generation Product. [*]. 

 7. Accepted
Unused Capacity. The following Section 5.10(a)(4)(i) shall be added to the Agreement: 
  

	 	5.10(a)(4)	

  

	 	(i)	After the Second Generation Process has been implemented at the Original Biberach Facility, Buyer shall have the ability to designate, at its sole discretion, that the Baseline
Accepted Unused Capacity shall be manufactured following either the First Generation Process or the Second Generation Process. 

 8. Effect of Amendment 6 on Agreement. Except as otherwise set forth in this Amendment No. 6, all other terms and provisions of the Agreement shall remain in full force and effect. In the event of any conflict between the terms
and conditions of the Agreement and the terms and conditions of this Amendment No.6, the terms and conditions of this Amendment No. 6 shall control. 
  

 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential
treatment that has been filed with the Securities and Exchange Commission. 
 3 

 Exhibit 10.63 
 9. Counterparts. This Amendment No. 6 may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute together one and the same instrument. 
 * 
 * 
 * 
 * 
 * 
 [continued on next page] 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
  

 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential
treatment that has been filed with the Securities and Exchange Commission. 
 4 

 Exhibit 10.63 
 IN WITNESS WHEREOF, the Parties have, by their duly authorized persons, executed this Amendment No. 6 as of the Amendment No. 6 Effective Date. 
 Boehringer Ingelheim Pharma GmbH & Co. KG 
 By: /s/ Uwe Buecheler 
 Name: Uwe Buecheler 
 Title: SVP Biopharmaceuticals 

Date: Dec. 14, 2007 
 Immunex Corporation 
 By: /s/ Madhavan Balachandran 
 Name: Madhavan Balachandran

 Title: SVP Manufacturing 
 Date: Dec. 6, 2007

 Wyeth, acting through its Wyeth 
 Pharmaceuticals
division 
 By: /s/ Robert J. Smith 
 Name: Robert
J. Smith 
 Title: Senior Vice President 
 Date:
Nov. 27, 2007 
  
  
  
  
  
  

 5 

 EXHIBIT A 
 SCOPE OF WORK 
 [*] 
  

 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential
treatment that has been filed with the Securities and Exchange Commission. 
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]